Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 178

Similar articles for PubMed (Select 23067262)

1.

Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia.

Lin KH, Lin YW, Wen YC, Lee LM.

Aging Male. 2012 Dec;15(4):246-52. doi: 10.3109/13685538.2012.724741. Epub 2012 Oct 15.

PMID:
23067262
2.

Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

Yu HJ, Lin AT, Yang SS, Tsui KH, Wu HC, Cheng CL, Cheng HL, Wu TT, Chiang PH.

BJU Int. 2011 Dec;108(11):1843-8. doi: 10.1111/j.1464-410X.2011.10233.x. Epub 2011 May 18.

PMID:
21592295
3.
7.

Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.

Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.

Eur Urol. 2012 May;61(5):917-25. doi: 10.1016/j.eururo.2012.01.013. Epub 2012 Jan 20.

PMID:
22297243
8.

A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M.

J Sex Med. 2012 Jun;9(6):1624-33. doi: 10.1111/j.1743-6109.2012.02718.x. Epub 2012 Apr 17.

PMID:
22510238
9.
10.

Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.

Suzuki H, Yano M, Awa Y, Nakatsu H, Egoshi K, Mikami K, Ota S, Okano T, Hamano S, Ohki T, Furuya Y, Ichikawa T.

Int J Urol. 2006 Sep;13(9):1202-6.

PMID:
16984553
14.
15.

Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).

Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, Garcia-Hernandez A, Klaver M, Traudtner K, Oelke M.

Eur Urol. 2013 Sep;64(3):398-407. doi: 10.1016/j.eururo.2013.03.031. Epub 2013 Mar 19.

18.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk